Centiva Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Centiva Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-84,187	Closed	-$1.41M	–	1830
2025 Q2	$1.41M	Buy	84,187 +60,031	+249%	+$969K	0.02%	470
2025 Q1	$371K	Buy	+24,156	New	+$431K	0.01%	972
2024 Q4	–	Sell	-50,037	Closed	-$902K	–	2372
2024 Q3	$902K	Buy	50,037 +1,514	+3%	+$26.5K	0.02%	911
2024 Q2	$788K	Buy	48,523 +17,966	+59%	+$277K	0.01%	901
2024 Q1	$431K	Buy	+30,557	New	+$385K	0.01%	1065
2023 Q3	–	Sell	-28,830	Closed	-$217K	–	2087
2023 Q2	$217K	Buy	28,830 +27,998	+3,365%	+$227K	﹤0.01%	1303
2023 Q1	$7.36K	Buy	+832	New	+$8.23K	﹤0.01%	1450
2022 Q3	–	Sell	-12,357	Closed	-$93K	–	1799
2022 Q2	$93K	Buy	+12,357	New	+$108K	﹤0.01%	1437

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Centiva Capital's TEVA Position: Q3 2025 in Review

Centiva Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 84,187 shares — an estimated $1.41M sold.

Centiva Capital first reported a position in TEVA in Q2 2022 and held it in 8 quarters. The position peaked at $1.41M in Q2 2025. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

Centiva Capital reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 84,187 Teva Pharmaceuticals shares in Q3 2025, an estimated $1.41M.
Centiva Capital first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Centiva Capital's Teva Pharmaceuticals position peaked at $1.41M in Q2 2025.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.